.png){kind=icon}
.png){kind=icon}
Return
Synthetic biology’s uncertain regulatory future in the wake of Loper Bright Enterprises v. Raimondo
.png){kind=icon}
PRE
AI
DOI：10.1038/s41587-026-03114-3.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The US Supreme Court’s decision in Loper Bright Enterprises v. Raimondo, along with federal spending cuts, may limit the potential of synthetic biology to provide innovative solutions for environmental challenges, medicine and biomanufacturing.
Keywords:
Policy
Technology
Life Sciences
general
Biotechnology
Biomedicine
Agriculture
Biomedical Engineering/Biotechnology
Bioinformatics
Journal
IF:
41.7
Papers:
1.2W
Citations:
10.1W